Higher cytotoxic activities of CD8
Cytokines
Cytotoxic T cells
Granzyme B
Immune cells
Lung Cancer
Natural killer cells
Journal
BMC immunology
ISSN: 1471-2172
Titre abrégé: BMC Immunol
Pays: England
ID NLM: 100966980
Informations de publication
Date de publication:
14 08 2023
14 08 2023
Historique:
received:
10
01
2023
accepted:
27
06
2023
medline:
16
8
2023
pubmed:
15
8
2023
entrez:
14
8
2023
Statut:
epublish
Résumé
Cytotoxic (CD8+) and natural killer (NK) cells play critical roles in anti-tumor immunity. Dysfunction in these cells is considered as one of the extrinsic mechanisms for tumor relapse. We aimed in this study to assess cytotoxic activities of CD8 + T and NK cells in the peripheral blood from lung cancer patients before and after induction of chemotherapy. Healthy (n = 5) volunteers and lung cancer patients (n = 15:5 before, 5 during, and 5 after induction of chemotherapy) were recruited. Flow cytometry was used to analyze the numbers of CD8 + T cells, NK and CD56 After culture, significant increases in the number of GzB expressing cells gated on CD3+, CD4+, CD8 + and NKCD8 + T cells in the PBMCs from lung cancer patients before induction of chemotherapy as compared to control individuals as well as patients during and after induction of chemotherapy. Serum levels of IL-1 and CXCL8 in patients before induction of chemotherapy showed 37- and 40-fold increases, respectively, as compared to control individuals. Both GzB expression and cytokines levels in patients during and after chemotherapy were similar. Polyclonal stimulation of PBMCs can restore the cytolytic activities of cytotoxic CD8 and NK cells from lung cancer patients even after chemotherapy.
Identifiants
pubmed: 37580655
doi: 10.1186/s12865-023-00553-4
pii: 10.1186/s12865-023-00553-4
pmc: PMC10426146
doi:
Substances chimiques
Cytokines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
24Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
J Appl Physiol (1985). 2002 Jun;92(6):2390-5
pubmed: 12015352
Cancer Immunol Immunother. 2019 Mar;68(3):395-405
pubmed: 30552459
Prostate. 2017 Jan;77(1):72-81
pubmed: 27604827
J Immunol. 2003 Dec 1;171(11):5727-35
pubmed: 14634080
Int J Cancer. 2015 Feb 1;136(3):547-59
pubmed: 24947242
Gene. 2019 Jul 1;704:91-96
pubmed: 30965130
Crit Rev Biotechnol. 2017 Mar;37(2):163-176
pubmed: 26767547
Front Immunol. 2017 Sep 22;8:1178
pubmed: 29018445
Oncogene. 2019 Jul;38(29):5792-5804
pubmed: 31243299
Br J Cancer. 2019 Jan;120(1):45-53
pubmed: 30413828
Cell Death Dis. 2019 Sep 20;10(10):695
pubmed: 31541080
Exp Mol Med. 2018 Dec 13;50(12):1-11
pubmed: 30546008
Immunol Lett. 2008 Oct 30;120(1-2):65-71
pubmed: 18672004
World J Clin Cases. 2019 Jun 6;7(11):1253-1261
pubmed: 31236389
Biol Open. 2019 Jun 28;8(7):
pubmed: 31208996
Adv Exp Med Biol. 2017;995:97-125
pubmed: 28321814
Expert Opin Biol Ther. 2011 Dec;11(12):1663-8
pubmed: 21995322
Theranostics. 2017 Apr 7;7(6):1543-1588
pubmed: 28529637
J Cancer. 2019 Jun 2;10(13):3021-3027
pubmed: 31281479
Front Immunol. 2019 Apr 26;10:877
pubmed: 31105699
J Rheumatol. 2019 Oct;46(10):1268-1276
pubmed: 30770498
Oncotarget. 2019 Nov 05;10(60):6456-6465
pubmed: 31741710
Nature. 2006 Jun 15;441(7095):890-3
pubmed: 16778891
Nat Med. 2001 Jan;7(1):114-8
pubmed: 11135625
Oncotarget. 2017 Jul 31;8(41):70431-70440
pubmed: 29050291
J Neuroimmunol. 2018 Aug 15;321:12-23
pubmed: 29957382
Molecules. 2019 Oct 09;24(20):
pubmed: 31600968
J Cancer Res Clin Oncol. 2018 Jun;144(6):997-1003
pubmed: 29616326
Cancer Immunol Immunother. 2009 Jan;58(1):49-59
pubmed: 18446337
Curr Opin Chem Eng. 2018 Mar;19:9-20
pubmed: 29623254
Cell. 2018 Apr 19;173(3):581-594.e12
pubmed: 29656895
Stem Cell Rev Rep. 2019 Apr;15(2):324-330
pubmed: 30397852
Cold Spring Harb Perspect Biol. 2018 Dec 3;10(12):
pubmed: 29101107
EMBO Mol Med. 2019 Apr;11(4):
pubmed: 30833304
Expert Opin Ther Targets. 2019 Jun;23(6):539-553
pubmed: 31079559
Methods Enzymol. 2020;632:215-228
pubmed: 32000897
Cancer Lett. 2021 Mar 1;500:163-171
pubmed: 33278498
Crit Rev Oncog. 2016;21(1-2):115-24
pubmed: 27481008
Clin Transl Oncol. 2019 Aug;21(8):961-976
pubmed: 30637710
Sci Rep. 2017 Jan 06;7:39692
pubmed: 28059079